The stock of Vertex Pharmaceuticals Incorporated (VRTX) has declined almost 13% in the past six months.A key reason for the stock price decline was unimpressive data from a phase II study on its key pipeline candidate, suzetrigine, for painful lumbosacral radiculopathy (LSR), a form of peripheral neuropathic pain, which showed largely undifferentiated pain reduction from placebo. Despite the unimpressive data in phase II, management decided to forge ahead to a phase III study in this indication, which is co ...

Have you been paying attention to shares of Vertex (VERX) ? Shares have been on the move with the stock up 5.8% over the past month. The stock hit a new 52-week high of $58.22 in the previous session. Vertex has gained 6.2% since the start of the year compared to the 37.2% move for the Zacks Computer and Technology sector and the 41.7% return for the Zacks Internet - Software industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn't missed our ...

KING OF PRUSSIA, Pa., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading global technology provider of indirect tax solutions, today announced that it will release fourth quarter 2024 financial results before the market opens on Thursday, February 27, 2025. A conference call to discuss the results will be held at 8:30 a.m. Eastern Time that same day. Those wishing to participate may do so by dialing 1-412-317-6026 approximately ten minutes prior to start time. A listen-only webcast of t ...

Vertex Pharmaceuticals NASDAQ: VRTX is a biotechnology company with a strong track record of success in developing treatments for cystic fibrosis (CF). Vertex is strategically expanding into the pain management sector, presenting a compelling growth opportunity for the company and its investors. As the global market seeks effective, non-opioid pain treatments, Vertex's advancements in this area could solidify its leadership in developing next-generation pain solutions, substantially increasing its market va ...

It usually doesn't matter if you buy a given stock immediately or two weeks later. Sure, the stock could move up or down but typically not enough to matter all that much.However, there are exceptions. Sometimes, a stock has a potential catalyst right around the corner. In such a case, investors could be much better off buying sooner rather than later.Vertex Pharmaceuticals (VRTX 3.06%) might be one of those special cases. Should you buy Vertex stock hand over fist before Jan. 30?A key date for VertexWhat's ...

On Sunday, Vertex Pharmaceuticals Incorporated VRTX announced multiple program updates, including:In December, the FDA approved Vertex's Alyftrek (vanzacaftor / tezacaftor / deutivacaftor), a once-daily triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. Vertex raised its CF patient estimates across major markets ...

KING OF PRUSSIA, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) ("Vertex" or the "Company"), a global provider of tax technology solutions, was recognized on Built In's 50 Best Remote Large Places to Work and 100 Best Remote Places to Work lists. This annual awards program recognizes companies of all sizes, from startups to enterprises, celebrating remote-first employers and those in large tech markets across the U.S. "What an incredible honor to be recognized by Built In – this award val ...

KING OF PRUSSIA, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, was recognized on Built In’s 50 Best Remote Large Places to Work and 100 Best Remote Places to Work lists. This annual awards program recognizes companies of all sizes, from startups to enterprises, celebrating remote-first employers and those in large tech markets across the U.S. “What an incredible honor to be recognized by Built In – this award val ...

Vertex (VERX) shares have skyrocketed 107.3% in the past 12 months, outperforming the Zacks Computer Technology sector, Zacks Internet Software industry and the S&P 500’s return of 38.1%, 40.3% and 26.8%, respectively. This strong performance highlights investor confidence in Vertex's innovative tax compliance solutions, strategic partnerships and expanding client base.Here's why adding Vertex to your portfolio makes sense now.Factors That May Benefit VertexThe increasing adoption of e-invoicing globally an ...

Vertex Pharmaceuticals (VRTX 0.72%) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to doubt the long-term potential of this stock, this setback is an opportunity to buy the dip for those who are willing to hold onto it for at least a few years. Here's why.This growth prospect just took a heavy hitVertex is best known for its therapies for the rare lung disease cystic fibrosis (CF). They provide the v ...